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Summary 
There are two immunogenic sites on the type A influenza A/Japan/57 (H2N2) hemagglutinin 
(HA)  that  can be recognized by class  I  major histocompatibility complex (MHC),  H-2K a- 
restricted cytolytic T lymphocytes (CTLs). One of these sites encompasses two distinct partially 
overlapping epitopes, which span HA residues 204-212 and 210-219. During the analysis of the 
fine specificity of CTL clones directed to the HA 210-219 epitope, we found that one clone 40-2 
also recognized the myeloma cell line P3x63-Ag8.  P3x63-Ag8 is derived from the MOPC 21 
myeloma and expresses  an immunoglobulin (Ig) heavy chain variable region (V.) gene which 
is a member of the murine 7183 V. gene family. Recognition was specific for the endogenously 
processed MOPC 21 heavy chain in association with the K a molecules,  since the SP2/0 derivative 
of P3x63-Ag8, which does not make a functional Ig H chain, is not recognized. The V. epitope 
recognized by clone 40-2 could be mapped to a 10 amino acid peptide spanning MOPC 21 V. 
residues 49-58. Cross-reactivity for the V, gene product was also demonstrable in some hetero- 
geneous populations of CTL generated in response to influenza virus infection. These results 
represent the first demonstration of cross-reactivity for an endogenously processed product of 
a  self-Ig by the CTL  directed to  a  foreign antigen and raise  the possibility  that  the Ig V. 
expression may regulate the CD8 §  T  cell response to foreign antigens. 
M 
ore than 30 years ago,  it was found that T  lympho- 
, cytes, unlike B lymphocytes, fail to discriminate between 
native and denatured protein antigens (1). Crucial observations 
over the last decade have led to the generally accepted belief 
that protein antigens must be processed by APCs into pep- 
tide fragments for recognition by T lymphocytes (2-4). These 
fragments associate with MHC molecules primarily in intra- 
cellular compartments.  The MHC molecules then present 
the antigenic fragments to T lymphocytes at the surface of 
APCs. Evidence now suggests that antigenic peptides recog- 
nized by CD8 § lymphocytes may be chiefly generated in the 
cytosol by proteolytic processing of peptides. The peptides 
are then translocated into the endoplasmic reticulum (ER) 1 
by MHC-linked transporter proteins (5-10). These peptides 
bind to class I MHC molecules and are believed to facilitate 
the stable assembly of class I MHC H chains and/32-micro- 
1 Abbreviations used in  this paper: EK,  endoplasmic reticulum; HA, 
hemagglutinin; RT, room temperature. 
globulin (8, 11). Extensive sequence analysis of antigenic pep- 
tides isolated from the clefts of class I MHC molecules demon- 
strated that  the endogenous antigenic peptide lengths are 
typically 8-10 amino acids, though longer peptides have also 
been found (12-16).  More importantly, allele-specific motifs 
have been identified for the epitopes recognized in associa- 
tion with particular class I MHC  alleles. 
Even though the potential T cell repertoire is very diverse, 
and the MHC molecules can bind a plethora of peptide frag- 
ments, the number of T cell epitopes for a given MHC haplo- 
type is surprisingly limited in a particular antigen (17-19). 
It has been shown that the expression of an allele-specific  MHC 
binding motif, though necessary, is not sufficient to render 
a site immunogenic (20).  Besides  good binding ability to 
specific MHC alleles, a protein antigen needs to be fragmented 
properly in the cytosol. The resultant peptide epitopes need 
to be translocated into the ER where they can complex with 
class I MHC molecules. In addition, the responding individual 
must have T lymphocytes with antigen receptors capable of 
recognizing the peptide-MHC  complex. 
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formation of self-peptide-MHC complexes in the thymus 
and/or the periphery can potentially regulate the T cells avail- 
able to react to foreign antigens through positive and/or nega- 
tive selection mechanisms. Ig V region gene products are a 
particularly rich source of self-peptides because of their great 
structural diversity.  They have been proposed as donors of 
self-peptides which can regulate the T lymphocyte repertoire 
(24-28). 
Influenza virus hemagglutinin (HA) is a target antigen for 
CD8 + CTLs (29). The influenza strain A/Japan/57 contains 
two immunodominant sites that are recognized by CD8 § 
CTLs in  association with the H-2K  d molecules (18, 30). 
One of these sites encompasses  two distinct partially over- 
lapping subsites  recognized by the different subsets  of K a- 
restricted CTLs (30). These overlapping sites span HA residues 
204-212 (LYQNVGTYV) and 210-219 (TYVSVGTSTL)  (30, 
and Hahn, C. S., Y. S. Hahn, V. L. Braciale,  C. M. Rice, 
and T. Braciale, manuscript submitted for publication). The 
magnitude of the CTL responses of H-2  d haplotype mice to 
these overlapping subsites is different (Myers-Powell,  B. A., 
V. L. Braciale, and T. J. Braciale, manuscript in preparation). 
The NH2-terminal nonamer epitope (JHA 204-212)  is im- 
munodominant,  eliciting  vigorous  CTL  responses  in 
A/Japan/57-immunized BALB/c mice. The CTL responses 
to the COOH-terminal decamer epitope (JHA 210-219) are 
weak and variable  among the immunized mice. 
During  the analysis of the specificity  of JHA 210-219- 
specific CTL clones on different target cells, we unexpect- 
edly found that a JHA 210-219-reactive  CTL clone 40-2 rec- 
ognized uninfected P3x63-Ag8 myeloma cells. This cell line 
expresses the murine MOPC 21 Ig V. gene product. In this 
report, we demonstrate that the HA-specific CTL clone 40-2 
recognizes an endogenously processed site within the MOPC 
21 V, which can be mapped to residues 49-58 in the CDR2 
of the H chain. This cross-reactivity is also seen in short term 
cultures of heterogeneous CTLs specific for the A/Japan/57 
HA. The significance of these findings for CTL repertoire 
development and the control of immunogenicity to foreign 
proteins by Ig V H regions is discussed. 
Materials  and Methods 
Mice.  BALB/cAnNTac (H-2  d) were purchased from Taconic 
Laboratory Animals and Services (Germantown, NY). 
Virus Stocks.  Influenza virus strains A/Japan/57 (H2N2 sub- 
type) was grown in the allantoic  cavity of 10-d-old chicken embryo 
and stored as infectious allantoic fluid at  -70~  (31). 
Cell Lines and CTL  Clones.  The P815 (H-2 d) mastocytoma 
cells were maintained in DME (GIBCO BILL, Gaithersburg, MD) 
supplemented with 10% (vol/vol) FCS and 1% (wt/vol)  gluta- 
mine. P3x63-Ag8 and SP2/0 myeloma cells were obtained from 
the American Type Culture Collection (RockviUe, MD) and main- 
tained as suggested (32). H17-L19, 17-L7-ZR1, IC3-3A4-1, and 
H35-C6-5 hybridomas  were generously  provided  by Dr. W. Gerhard 
(The Wistar Institute of  Anatomy and Biology, Philadelphia, PA), 
and maintained as described  elsewhere (32). CTL clones 14-7, 40-2, 
and NI 12 were isolated CTL precursors primed with influenza 
A/Japan/57 virus and established as previously described (18, 30). 
They were passed weekly in the presence of irradiated influenza 
A/Japan/57-infected splenocytes  and a source of exogenous T cell 
growth factor. 
Peptides.  Synthetic  oligopeptides  were produced  either on a rapid 
amide multipeptide  synthesis system (RaMPs  |  NEN-DuPont, 
Boston, MA) or an automated Solid Phase Peptide  Synthesizer  from 
Applied Biosystems,  Inc. (Foster City, CA). HPLC analysis  showed 
that peptides were >95% pure. Stock solutions of synthetic pep- 
tides were dissolved  in 100% DMSO at concentrations  of  5 mg/ml, 
and diluted to the desired concentrations in MEM immediately  be- 
fore use in cytotoxicity assays. Control experiments have shown 
that DMSO at concentrations used in the assays has no effect on 
target viability or CTL function. 
Bulk CTL Populations.  Mice  were primed intraperitoneaUy  with 
"~103 hemagglutinin units of infectious A/Japan/57  virus. 3 wk 
later, splenocytes  were removed and restimulated in vitro with ir- 
radiated A/Japan/57-infected  splenocytes. The third passage was 
done by using JHA 210-219 peptide pulsed splenocytes. Cultures 
were assayed  for cytolytic  activity after 5-7 d of incubation at 37~ 
CTbmediated Cytolysis Assay.  The P815 (H-2  d) cells were used 
as target cells in a 51Cr-release assay as previously described (30). 
51Cr-release assay was also used to assess peptide competition in 
4-h cytotoxicity assays. Competing peptides at appropriate con- 
centrations were incubated with labeled P815 for 15 min at room 
temperature (RT)  in 96-well microtiter plates before clone 14- 
7-specific peptide JHA 523-545 was added. After another 15 min 
at RT, clone 14-7 cells were added at an E/T ratio of 5 to 1. 
Results 
Lysis of  P3x63-Ag8 Myeloma by a HA-specific Class I MHC- 
restricted CTL Clone.  CTL clone 40-2 is a H-2Kd-restricted 
CD8 +  clonal T  cell  line derived from BALB/c mice im- 
munized with infectious A/Japan/57  virus. It recognizes  a 
site in the A/Japan/57 HA that can be mapped to residues 
210-219 (JHA210-219).  During the analysis of the fine speci- 
ficity of this influenza-specific clone, we unexpectedly found 
that clone 40-2 lysed the uninfected BALB/c myeloma cell 
line P3x63-Ag8 (P3) (Fig. 1). This drug-resistant hybridoma 
fusion partner is derived from the MOPC 21 myeloma (33). 
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Lysis of myeloma  P3x63-Ag8 by the A/Japan/57 HA 210-  Figure  1. 
219-specific CTL clone  40-2. SlCr-labeled  P3x63-Ag8 (11) or SP2/0 (D) 
myeloma  cells were incubated  with  JHA 210-219-specific CTL clone  40-2 
or NI 12 for 4.5 h at 37~  Different E/T ratios were used as shown. 
The percent specific  cytolytic  activity  from quadruplicate  samples  was cal- 
culated. Spontaneous lysis has been subtracted from the values shown. 
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Figure  2.  Recognition of the MOPC 21 V. 49-58 peptide  by CTL 
clone 40-2. (A) Amino acid sequences of JHA 210-219 homologous pep- 
tides  in MOPC  21  V. and A/AA/57  HA.  Those residues  framed  by 
dashed lines are the residues conserved between JHA 210-219 and MOPC 
21 V. 49-58.  Residue  215 is different between JHA 210-219 and AHA 
210-219 (underlined). Arrows highlight residues believed to be critical for 
K d binding.  (B and C) 51Cr-labeled P815 target cells were incubated alone 
or in the presence of synthetic peptides representing JHA 210-219 (--t~), 
MOPC  21  VH  49-58  (--IF),  or  AHA  210-219  (-2k-).  JHA  210- 
219-specific CTL clone (B) 40-2 or (C) NI 12 was added to targets  and 
incubation  continued for 4 h at 37~  The E/T ratio for each assay was 
5:1. The percent specific cytolytic activity from quadruplicate samples was 
calculated.  Nonspecific killing was 2.6% by clone 40-2,  0.5% by clone 
NI 12. 
was very efficient with lysis demonstrable over a range of 
effector to target ratios.  The lysis of the P3 myeloma was 
not nonspecific. The H-2Kd-restricted clone NI-12 did not 
lyse P3 cells (Fig.  1). This CTL clone, like 40-2, is directed 
to the JHA 210-219 site but differs in fine specificity from 
clone 40-2.  Clone 40-2 recognizes the JHA 210-219 site but 
not the corresponding site in the A/AA/57 virus (AHA 210- 
219) which differs from theJHA 210-219 by one residue (Set 
for Gly at position 215) (Fig. 2 A) (30).  Clone NI 12 recog- 
nizes bothJHA 210-219 and AHA 210-219 with comparable 
efficiency. 
Whereas clone 40-2  lysed uninfected P3 cells, it did not 
lyse the SP2/0 myeloma cell line (Fig.  1). This cell line is 
a variant of P3 which does not express the MOPC  21 VH 
gene (34).  SP2/0 was however readily lysed by clone 40-2 
after pulsing with the decamer synthetic peptide corresponding 
to the JHA 210-210 epitope (data not shown). 
Crossrecognition of a MOPC 21  V,, Peptide by CTL  Clone 
40-2.  The observation of lysis by clone 40-2 of the unin- 
fected P3 cell line hut not the SP2/0 cell line raised the possi- 
bility that clone 40-2 recognized, in a cross-reactive manner, 
a processed epitope derived from the MOPC  21  V. gene 
product. The decamer epitope in the A/Japan/57 HA rec- 
ognized by clone 40-2 contains a Tyr residue at position 2 
and Thr and Leu residues at position 9 and 10. This is a motif 
defined by Healy et al.  (20)  and Komero et al.  (35)  to be 
critical for  peptide  binding  to  K d.  An  inspection  of the 
MOPC  21 V, amino acid sequence (33)  revealed  that  this 
K d binding motif was contained within a 10 amino acid seg- 
ment  of the  MOPC  21  V..  This  segment  encompasses 
residues 49-58  and partially overlaps  the CDR2 region of 
the MOPC 21 V. (Fig. 3). The V. 49-58 sequence has 6 of 
10 residues in common with JHA 210-219. This includes, 
in addition to the Y50 at position two and the T57 and L58 
at positions 9 and 10 in the sequence, $52,  G54,  and $56, 
corresponding to $213, G215, and $217, in the JHA 210-219 
sequence (Fig.  2 A). 
To determine if the cross-reactivity of clone 40-2  for P3 
cells could be due to recognition of the MOPC 21 V~ 49-58 
site, we made a synthetic peptide corresponding to the MOPC 
21 V. 49-58  site and tested clone 40-2  for recognition of 
H-2K<bearing P815 cells treated with the V. 49-58 peptide. 
As Fig. 2 B shows, clone 40-2 recognized the V. 49-58 pep- 
tide at peptide concentration down to 10-12-10-11  M with 
an efficiency similar to that of the JHA 210-219 peptide. In 
contrast, clone NI 12 recognizes P815 target cells treated ei- 
ther with the JHA 210-219 peptide or the AHA 210-219 pep- 
tide with a similar efficiency, but does not recognize target 
cells pulsed with the V, 49-58 peptide (Fig. 2 C). This sug- 
gests that treatment of cells with the V. 49-58 peptide does 
not render cells susceptible to nonspecific lysis. 
The efficient recognition of the V. 49-58 peptide implied 
that this peptide would also bind to the H-2K  d molecule on 
cell surfaces. We examined the V. 49-58 peptide binding to 
K d in a peptide competition assay. In this assay, the capacity 
of  the  V.  49-58  and  JHA  210-219  peptides  to  inhibit 
binding and subsequent CTL recognition of a K a binding 
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Figure  3.  Sequences  of four hybridoma  cell  lines using 
different members of the 7183 V. gene family (32). The 
regions homologous  to JHA 210-219 are framed  by dashed 
lines. 
peptide corresponding to an epitope in the transmembrane 
domain of the A/Japan/57 HA was analyzed. As Fig. 4 shows, 
both the JHA 210-219 and V, 49-58 peptides inhibited rec- 
ognition of the transmembrane peptide by the CTL clone 
with a comparable efficiency. The synthetic JHA 129-145 pep- 
tide which does not bind K a failed to compete. 
Recognition of MOPC 21  V, Expressing Hybridoma Cell 
Lines by Clone 40-2.  Our analysis  with  the  synthetic V. 
49-58  peptide  supported  the  view  that  an  endogenously 
processed fragment of the MOPC 21 V. was recognized on 
P3 cells by the influenza-specific CTL clone 40-2. The MOPC 
21 V. gene is a germline member of the 7183  murine V. 
gene family (36). If clone 40-2 does recognize a site in the 
MOPC  21 V, encompassing residues 49-58,  we anticipate 
that  other  H-2K  a  haplotype  hybridomas  expressing  the 
MOPC  21  V.  gene would be recognized by clone 40-2. 
Also, hybridomas utilizing other members of the 7183  Ig 
V,  family  with  sequence  difference in  the  49-58  region 
should not be recognized by clone 40-2.  As Fig.  5 shows, 
this is indeed the case. Two independently derived hybrid- 
omas H17-L19 and 17-L7-ZR1 (32) express the MOPC 21 
V. gene and are lysed by clone 40-2.  Two other hybridomas, 
IC-3A4-1 and H35-C6-5  (32), use two other members of 
the 7183 V. gene family. These V. genes are highly homol- 
ogous to the MOPC 21 V. gene but do not contain the crit- 
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Figure  4.  Inhibition  of CTL-mediated  lysis  of  JHA 523-545-sensitized 
targets by JHA 210-219 and MOPC 21 V. 49-58 peptides. 51Cr-labeled 
P815 target cells were incubated 15 min at RT with JHA 210-219 (--O-) 
or MOPC 21 V. 49-58 (--I-) peptides at various concentrations. 1.0 
#g/ml JHA 523-545 peptide was then added and incubation at RT con- 
tinued for another 15 min before the addition of JHA 523-545-specific 
CTL clone 14-7. The non-K  a binding peptide  JHA 129-145 (~)  was 
used as a control. The assay time was 4.5 h, and the E/T ratio was 5:1. 
The percent  specific  cytolytic  activity  from quadruplicate  samples was cal- 
culated. 
binding to K a (Fig.  3). These two hybridomas are not rec- 
ognized by clone 40-2. Again, clone NI 12 does not lyse any 
of the hybridoma targets. 
Recognition of the Processed  MOPC 21  V, Gene Product by 
Heterogeneous  Populations of Influenza-specific CTLs.  Clones 
40-2 and NI 12 were independently derived from splenocyte 
cultures of BALB/c mice infected in vivo with A/Japan/57 
virus.  Bulk cultures of immune splenocytes were then re- 
stimulated with infectious virus in vitro for three to four pas- 
sages before cloning on A/Japan/57 infected splenocyte feeders. 
Because clone 40-2 has been maintained in long-term in vitro 
cultures, it was of interest to assess if the cross-reactivity of 
JHA 210-219-reactive CTLs for the P3 myeloma and the V. 
49-58 peptide was demonstrable among virus-specific CTL 
in short-term in vitro cultures. To address this, we examined 
JHA 210-219-specific T cells in short-term culture for reac- 
tivity.toward P3 and V. 49-58. Splenocytes from each of five 
A/Japan/57-infected  BALB/c mice were restimulated in vitro 
with infectious A/Japan/57 virus and individually tested for 
reactivity on  several  Kd-restricted epitopes  and  for cross- 
reactivity on P3 cells. 
Although  the  Ka-restricted CTL  responses  to  the  im- 
munodominant influenza nucleoprotein (NP)  147-158  epi- 
tope and the JHA 204-212 epitope were readily demonstrable, 
the response to the JHA 210-219 epitope was weak and vari- 
able for each mouse (i.e.,  "20% of the response to the NP 
147-158 site) (data not shown). To amplify the response to 
theJHA 210-219 epitope, virus-immune splenocytes were re- 
stimulated in vitro with the JHA 210-219 peptide. 7 d after 
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Figure 5.  Lysis  of MOPC 21 Va-expressing  hybridoma  cells by CTL 
clone 40-2. slCr-labeled  H17-L19 (11), 17-L7-ZR1 (D), IC5-3A4-1 ([]), 
or H35-C6-5 ([]) hybridoma  cells were incubated with CTL clone  40-2 
or NI 12 for 5.5 h at 37~  Different  E/T ratios were used as shown. 
The percent  specific  cytolytic  activity  form  quadruplicate  samples was cal- 
culated. Spontaneous lysis has been subtracted from the values shown. 
198  Cross-recognition  of a Self-Peptide I00 - 
80  = 
"~  611 = 
"~  411  - 
21)  - 
o 
-20  -  I ol  I.j 
eq  O  eq  ~ 
<  ~  < 
=  +  =  z 
m  + 
m 
Figure 6.  Specificity  of A/Japan/57-immune  cytolytic  T lymphocytes. 
Five BALB/c  mice  were primed with A/Japan/57 virus. Immune  spleno- 
cytes from each animal were individually  stimulated  in vitro 3 wk later 
with A/Japan/57-infected splenocytes.  After  two passages, the individual 
bulk cultures were restimulated  with peptide  JHA 210-219-pulsed spleno- 
cytes. The activated  CTLs  were used in a standard  6-h cytotoxicity  assay 
with slCr-labeled  P815 target cells and 0.01 #g/ml peptide, or SlCr-labeled 
myeloma  P3x63-Ag8 or SP2/0. The E/T ratio  was 10:1. The percent  specific 
cytolytic  activity  from  quadruplicate  samples  was calculated.  Spontaneous 
lysis has been subtracted  from the values  shown. The five  bar grafts  repre- 
sent the response of the individual mice on each target cell group. 
tested for reactivity on peptide-treated P815 cells and P3 my- 
eloma cells. As Fig.  6 shows,  cultures derived from all five 
animals recognize JHA 210-219 pulsed target cells as expected. 
In vitro stimulation with JHA 210-219 peptide enriches for 
JHA 210-219-reactive  CTLs, and the reactivity to the NP 
147-158 epitope is lost. Of particular interest is the finding 
that only one culture in five bulk cultures shows reactivity 
to the P3 myeloma cell and to target cells treated with the 
MOPC 21 V. 49-58 peptide. This reactivity pattern in het- 
erogeneous cultures is characteristic of specificity of the clone 
40-2.  Likewise, only one culture among the others showed 
reactivity for the AHA 210-219 peptide, which is character- 
istic of the NI 12 clonal specificity.  Importantly, the bulk 
culture from the A/Japan/57-immune individual which rec- 
ognized the  MOPC  V.  49-58  peptide was  also  the only 
CTL population that lysed uninfected P3 myeloma cells. Thus 
cross-reactivity  for the MOPC 21 V. was also demonstrable 
in short-term bulk cultures of specific CTL from an influenza 
virus-immunized mouse. 
Discussion 
In this report, we have examined the structural basis for 
the unexpected cross-reactivity exhibited by a class I MHC-re- 
stricted influenza HA-specific CTL clone 40-2 for the P3x63- 
Ag8 myeloma cell line. We found that recognition and lysis 
of the myeloma cell line requires  expression  of the MOPC 
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21 V. gene since the MOPC 21 V, nonexpressor SP2/0 is 
not recognized by clone 40-2.  The MOPC 21 V. has a 10- 
amino acid segment spanning CDR2 residues 49-58 which 
contains a sequence motif critical for peptide binding to the 
K a molecule (35). Clone 40-2 recognizes target cells treated 
with a synthetic decamer peptide corresponding to the MOPC 
21 V. residues 49-58.  This K a binding peptide is recognized 
as efficiently  by clone 40-2 as the JHA 210-219 peptide. The 
MOPC 21 V. gene is a member of the murine 7183 Ig V. 
gene family. Hybridomas expressing other 7183 Ig V, mem- 
bers that are highly homologous to the MOPC 21 VH but 
lack this K d binding motif in the CDR2 region were not 
recognized by clone 40-2. Importantly, cross-reactivity of  JHA 
210-219-reactive  T cells for the MOPC 21 V. gene product 
was not only seen with the 40-2  clone but also seen with 
a heterogeneous population of  JHA 210-219-reactive  CTLs 
derived from short-term cultures of influenza virus-immune 
splenocyte CTL precursors.  Thus, this cross-reactivity is not 
the unique property of a long-term CTL clone, but rather 
demonstrable in virus-immune T cell populations. Taken to- 
gether,  these  data  strongly  suggest  that  some  influenza 
virus-specific CD8 + CTL can specifically recognize an en- 
dogenously processed  fragment  of a  murine  Ig  VH  gene 
product. 
Unlike clone 40-2,  clone NI-12  does not recognize the 
MOPC 21 VH 49-58  site, but does recognize the HA 210- 
219  site of both the A/Japan/57 and the A/AA/57 virus. 
The JHA 210-219 and AHA 210-219 sites differ by one res- 
idue (a Gly -~ Set substitution at position six in the pep- 
tide). As discussed below, this residue may be critical for 40-2 
recognition of the peptide-MHC complex, since clone 40-2 
does not recognize A/AA/57 virus or the AHA 210-219 pep- 
tide. It is also noteworthy that the CTL specificities com- 
parable to the 40-2 and the NI-12 clonal specificities are rep- 
resented as dominant specificities in bulk populations of HA 
210-219-reactive  CTLs from different individual mice. 
Earlier  studies by Romero and co-workers (20,  35) have 
implicated the Tyr at position two and the Thr/Leu at posi- 
tions 9 and 10 as critical for decamer peptide binding to the 
K d molecule. We have modeled the JHA 210-219 peptide 
into a three-dimensional crystal  structure of the K d mole- 
cule based on the HLA-A2 coordinates (37). In our prelimi- 
nary computer modeling, the Ser, Val, Gly, and Thr at posi- 
tions 4,  5,  6,  and 9 of JHA 210-219 are solvent accessible 
and represent potential TCR contact residues. TheJHA 210- 
219  site  and the  MOPC  21  V~  49-58  site  have  identical 
residues at positions 4, 6, and 9. It is likely that one or sev- 
eral of these residues is critical for peptide recognition by the 
40-2 TCR. Consistent with this view is our finding that the 
AHA 210-219 site which differs by only one residue,  a Gly 
--* Ser change at position 6, is not recognized by clone 40-2. 
Clone NI-12, on the other hand, recognizes both viral pep- 
tides but not the MOPC 21 V. 49-58  peptide.  These data 
suggest that the difference in the amino acids occupying po- 
sitions accessible to the TCR could account for the variability 
in the recognition of these related decamer peptides. 
The cross-reactivity of virus-specific  CTLs for an Ig V. 
site raises the possibility that the CTL repertoire to foreign antigens might be regulated at the level of Ig V, expression. 
The Kd-restricted CTL response to the JHA 210-219  site is 
weak relative to the vigorous Kd-restricted CTL responses 
to theJHA 204-212 site and the NP 147-158  site. More than 
20 H-2  a haplotype mice of different strains  have been exam- 
ined by us and show a consistent pattern of weak responsive- 
ness to the JHA 210-219  site.  (Myers-Powell, B. A.,  and S. 
Tykodi, unpublished data). This is not due to defective pro- 
cessing of the JHA 210-219  site,  as mice immunized  with 
a viral vector expressing the preprocessed 210-219  site also 
mount  a weak response  (Myers-Powell, B. A.,  manuscript 
in preparation).  Rather, this weak response may reflect a limited 
repertoire of CTL precursors available to respond to the JHA 
210-219 site. Consistent with this view is the apparent limited 
heterogeneity in the response to theJHA 210-219 site in bulk 
cultures  from individual  mice reported here.  As shown in 
Fig. 6, CTLs from one animal exhibits a fine specificity similar 
to clone 40-2 with recognition of the JHA 210-219  epitope 
and the MOPC 21 V~ site,  but not the AHA 210-219  epi- 
tope. Another individual shows the fine specificity of clone 
NI-12 with recognition of the JHA 210-219 and AHA 210- 
219 epitopes, but not MOPC 21 V. reactivity. Three other 
mice recognize  the JHA 210-219  site exclusively. 
A limited repertoire diversity to a Ka-restricted CTL epi- 
tope was also noted by J.-L.  Casanova et al.  (38).  In  that 
instance,  the authors suggested that the structural homology 
of that epitope for a self-peptide derived from the K d mole- 
cule itself could result in T lymphocyte deletion in the thymus 
and account for the limited heterogeneity in the response to 
that epitope. Thus, an intriguing explanation for the limited 
response to JHA 210-219 is that the expression of the MOPC 
21  V.  gene regulates  the response to  this  viral  epitope.  B 
cells and their Ig gene products have been proposed as im- 
portant regulators of T cell responsiveness, and evidence for 
recognition of Ig gene products by T cells has been reported 
(22-27).  The  simplest mechanism  to explain  the weak re- 
sponse to JHA 210-219  and the variable cross-reactivity for 
MOPC  21  V.  49-58  is that  the expression of the MOPC 
21 V. gene product by B cell results in cross-tolerance to the 
JHA 210-219 epitope. Therefore, in four of the five mice ex- 
amined, expression of the MOPC 21 VH results in deletion 
or anergy of the majority of JHA 210-219-reactive T  cells 
including all CTL precursors that cross-react with the MOPC 
21  V..  In one of five individuals,  the MOPC 21 V. gene 
product is not expressed or not expressed at a sufficient level 
to  completely eliminate  all  of the  MOPC  21  VH-reactive 
CD8 + clones. 
At present we cannot exclude a positive selection model 
where the expression of the MOPC 21 VH gene is required 
to amplify the clonal repertoire to theJHA 210-219 epitope. 
In this connection, it is noteworthy that MOPC 21 gene is 
a member of the 7183 murine V. gene family.  This family 
is the closest one to the D/J gene segment and may rear- 
range early in B cell development (36, 39). Thus,  the gene 
family and its individual members could provide an impor- 
tant positive selective pressure in the development of the T 
cell repertoire to foreign antigen (26, 27). A detailed analysis 
of MOPC 21 V. gene expression and JHA 210-219 respon- 
siveness in individual mice is ongoing and should distinguish 
these models for CTL repertoire regulation. 
This report provides, we believe,  the first  demonstration 
of cross-reactivity by CD8 + CTL directed to a foreign an- 
tigen  site for an endogenously processed Ig VH gene pro- 
duct.  This cross-reactivity, which is detectable both at the 
clonal level and in bulk cultures, seems more than fortuitous. 
Rather,  it may reflect  an ongoing process of T  lymphocyte 
repertoire  selection and  molding  by Ig V,  gene products. 
The germline Ig V. genes are an obvious source of diverse 
peptides that could regulate T  lymphocyte selection in the 
thymus or regulate the state of activation or anergy of ma- 
ture T  lymphocyte precursors in the periphery.  We do not 
as yet know if the T  lymphocyte repertoire molding by Ig 
gene products is solely at the level of responses to an individual 
antigenic epitope or if it can effect the CTL response to a 
microorganism. Understanding the influence oflg gene prod- 
ucts on T lymphocyte function and repertoire development 
will be important in understanding the regulation of T lym- 
phocyte responses to foreign antigens during infections and 
to  self-proteins during  autoimmune  diseases. 
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